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Human cells express thousands of different surface proteins that
can be used for cell classification, or to distinguish healthy and
disease conditions. A method capable of profiling a substantial
fraction of the surface proteome simultaneously and inexpen-
sively would enable more accurate and complete classification
of cell states. We present a highly multiplexed and quantitative
surface proteomic method using genetically barcoded antibod-
ies called phage-antibody next-generation sequencing (PhaNGS).
Using 144 preselected antibodies displayed on filamentous phage
(Fab-phage) against 44 receptor targets, we assess changes in B
cell surface proteins after the development of drug resistance in
a patient with acute lymphoblastic leukemia (ALL) and in adap-
tation to oncogene expression in a Myc-inducible Burkitt lym-
phoma model. We further show PhaNGS can be applied at the
single-cell level. Our results reveal that a common set of proteins
including FLT3, NCR3LG1, and ROR1 dominate the response to sim-
ilar oncogenic perturbations in B cells. Linking high-affinity, selec-
tive, genetically encoded binders to NGS enables direct and highly
multiplexed protein detection, comparable to RNA-sequencing for
mRNA. PhaNGS has the potential to profile a substantial frac-
tion of the surface proteome simultaneously and inexpensively
to enable more accurate and complete classification of cell states.
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Next-generation sequencing (NGS) has revolutionized ourability to sensitively and broadly detect and quantify DNA
and RNA sequences, even at the single-cell level (1, 2). Although
RNA-sequencing (RNAseq) is sensitive and highly multiplexed,
mRNA levels do not necessarily correlate with protein abun-
dance (3). Here we describe an approach for multiplexed detec-
tion of membrane proteins on cells using genetically barcoded
antibody-phage.
Key to the technology we call phage-antibody NGS (PhaNGS)
is a collection of defined fragment antibodies (Fabs) previously
selected to bind specific targets of interest using high-throughput
phage display (SI Appendix, Fig. S1) (4–6). Each Fab-phage
was selected from a large synthetic Fab library (∼1010 unique
sequences) built from a stable, VH3-Vκ1-based Trastuzumab
scaffold (7) and validated for affinity and selectivity. The selected
Fabs are genetically encoded and displayed on a phage parti-
cle that packages its specific Fab gene within (Fig. 1A). Taking
inspiration from previous work that linked deep sequencing and
phage libraries (8), we reasoned that the individual Fab-phage
can be distinguished and quantified by NGS of the highly variable
complementarity determining region (CDR) H3 loop, which rep-
resents both the major binding determinant of the encoded Fab
and a unique DNA barcode. The fixed scaffold in which the CDR
is embedded allows the use of a common set of primers flank-
ing the H3 region for amplification and sequencing (SI Appendix,
Fig. S2) (9). We hypothesized that a pool of preselected Fab-
phage specific for a defined set of extracellular proteins would
bind their cognate proteins on cells at levels in proportion to
receptor abundance and allow for target quantification by NGS
(Fig. 1B). The displayed Fab is attached to the phage on the
opposite end from its antigen binding site and is known to retain
virtually the same affinity for its target as when expressed as sol-
uble Fab (SI Appendix, Fig. S3) (10).
Results
Validation of the PhaNGS Method in Model Experiments. To assess
the feasibility of the approach, we used simple phage titering
to measure binding of an anti-GFP Fab-phage (GFP-phage) to
HeLa cells engineered to express a membrane-anchored GFP
or parental (Fig. 1C). After binding and washing, we found 400
times more phage on the GFP-expressing cells than control cells.
A control Fab-phage directed to the intracellular transcription
factor ZNF2 showed similar low-titer binding to either cell line.
To assess the sensitivity of detection of GFP-phage, we immo-
bilized varying concentrations of GFP on beads ranging from
about 2 pM to 20 µM. Eluted phage titers were linear over a 4-log
range and showed detectable signal over background (defined as
BSA binding) with as little as 30 pM of immobilized GFP (Fig.
1D). We also observed that the fractional recovery of GFP-phage
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Fig. 1. Design and validation of the PhaNGS method. (A) The Fab is fused
to the gene III coat protein on the M13 phagemid within the viral parti-
cle. Each phage antibody is preselected for binding to specific proteins and
can be uniquely identified by the sequence of its CDR H3 (green bar). (B)
Diagram of the PhaNGS method, which consists of three steps: (i) A collec-
tion of phage antibodies is assembled that bind to specific targets of inter-
est; (ii) the library is bound to a cell sample, and nonbinding phage anti-
bodies are washed away; and (iii) the bound phage antibodies are prop-
agated, amplified, and subjected to next-generation DNA sequencing to
quantify the retained phage antibodies. (C) One antitarget (GFP.01, n = 3)
and one control phage (ZNF2.01, n = 3) were profiled against a HeLa line
stably overexpressing GFP tethered to the cell surface (green bar), along
with its parental line (gray bar) and a no-cell control. Error bars show SD of
three replicates. Input titer for GFP/ZNF2 phage was measured at 3 × 1011/
4 × 1011 cfu/mL. The phage titers after binding and washing were 3 × 107/
8 × 104 cfu/mL for HeLaGFP, 4 × 104/5 × 104 for the HeLa cell control, and
undetectable for the no-cell control. (D) To investigate the limit of detec-
tion of PhaNGS, a single, strong phage (Kd = ∼0.5 nM at 2 × 1011 cfu/mL)
was panned against varying concentrations of immobilized GFP (green tri-
angles) or BSA alone (dashed line), acid eluted, and titered. Results are
shown below the graph. A total of 3.4 pM of GFP was indistinguishable
from BSA, however 34 pM appeared to be above the detection limit, which
we approximate here at a titer of ∼106 cfu/mL phage at around 10 pM
GFP. To obtain a value for the fraction of infective phage actually express-
ing a Fab, the same data are displayed as fraction of phage pulled down.
We see the fraction level off at around 0.1, suggesting that 10% of GFP.01
phage actually display a Fab. (E) A mock phage mixture was assembled
from four different Fab-phage clones with concentrations ranging from
105−8 cfu/mL, a 4-log range expected to match the range present on cells
(14) and expected phage titers from above, to examine the accuracy and
dynamic range of the PhaNGS method. Propagating the phage mixture to
saturation in culture followed by PCR was more accurate than direct PCR
without propagation.
peaked at 0.1, implying that about 10% of total phage particles
for this clone display a Fab. This is consistent with earlier esti-
mates of Fab display in monovalent phage format (11).
We next investigated the most efficient means of amplify-
ing phage DNA for NGS over a 4-log range of concentration,
either by direct PCR or by first propagating the Fab-phage in
Escherichia coli to saturation followed by PCR (Fig. 1E). We
found that propagation and PCR more closely matched the
expected results than PCR alone, most likely because fewer
rounds of PCR introduce less amplification bias (12). Bradbury
and coworkers have shown that polyclonal pools of scFv-phage
have similar replicative rates independent of the scFv (13). We
tested this hypothesis for a pool of 155 Fab-phage clones with
roughly equal starting titers and found little replicative advan-
tage in the pool based on NGS counts (SI Appendix, Fig. S4).
Indeed, after multiple rounds of propagation from 105 cfu/mL to
1011 cfu/mL, we saw only two clones with an obvious replicative
advantage over the other Fab-phage in the pool.
Assembly and Validation of the PhaNGS Library. We then assem-
bled a larger pool of Fab-phages, which grew to encompass 179
clones preselected for high affinity and selectivity to bind 59
purified ectodomain targets broadly associated with cancer and
immunology (SI Appendix, Fig. S5, and Dataset S1). We decided
to include multiple Fab-phage per target to provide independent
measures and to test if certain epitopes were more responsive
than others. In the pool, we had an average of four unique Fab-
phage per target with a range of one Fab-phage for some targets
to up to 13 for others. The Fab-phage pool also includes ZNF2-
and GFP-phage background controls, against which the raw NGS
counts obtained from antisurface protein Fab-phages can be nor-
malized to determine signal and define nonspecific binding (see
Dataset S3).
To test this assembled PhaNGS library, we first profiled
HEK293T cells, a standard human expression host derived from
human embryonic kidney cells (SI Appendix, Fig. S6). We found
that most Fab-phage in the pool showed comparable signal to
the nonspecific controls, while about a dozen targets gave sig-
nificant signal over background, including the tyrosine kinase
receptors EGFR, EPHA4, FGFR4, FLT3, INSR, ROR1, and
TYRO3. To determine how overexpression affects Fab-phage
signal strength, we generated a tetracycline (Tet)-inducible con-
struct for CDCP1, one of the targets basally expressed at back-
ground (SI Appendix, File S2). Upon induction with Tet, the NGS
signal for each of three CDCP1-phages in the pool increased
dramatically to between 50- and 80-fold above background, with
small SDs between replicates. In other control experiments with
GFP-phages of known affinity, we found that the NGS signals
vary in rough proportion to affinity (SI Appendix, Fig. S7). Thus,
we expect signal variation between unique Fab-phages to the
same target is due to affinity differences.
PhaNGS Profiling of Diagnosis-Relapse Samples in Leukemia. We
next applied the pool of Fab-phages to profile B cells from
an ALL patient before and after chemotherapy. Samples were
obtained from the bone marrow of the patient at diagnosis
(LAX7D) and after the development of resistance (LAX7R) fol-
lowing a standard 3-wk chemotherapy regimen (see Fig. 2A and
Materials and Methods for sample details) (15). PhaNGS pro-
files on LAX7D and LAX7R were performed in quadruplicate
and showed a 1,000-fold signal range (Fig. 2B). Out of the 144
antitarget phages used in this experiment, 125 showed significant
signal above background in either the LAX7D or LAX7R condi-
tions. These phages fell into several groups: About one-third of
the Fab-phages showed little change in NGS signal between the
LAX7D and LAX7R cells, suggesting little net change in target
expression. The remaining clones fell into two groups (Fig. 2C):
one where the target protein was high at diagnosis and decreased
up to 10-fold in relapse (such as for ROR1 and NCR3LG1), and
another where the target was low at diagnosis and increased up to
100-fold at relapse (such as for FLT3 and PDGFRB). FLT3 has
previously been observed to be overexpressed and/or mutated in
ALL and acute myeloid leukemia (AML) (16, 17). ROR1 also






Fig. 2. PhaNGS profiling of surface proteomes at diagnosis and relapse in a patient with acute lymphoblastic leukemia (ALL). (A) Bone marrow samples
obtained from a patient diagnosed with ALL (Ph-negative) at diagnosis (LAX7D) and relapse (LAX7R) were grown as xenografts into immune-compromised
NOD/SCIDγc–/– mice, cocultured with OP9 cells, and later frozen as monoculture stocks. Samples were thawed and expanded in culture 1 wk before the
PhaNGS profile experiment. Both cell populations were positive for CD10, CD19, and CD45. The LAX7R resistance sample possessed a KRASG12V mutation not
detected at diagnosis. (B) PhaNGS profiles for 144 different Fab-phages (SI Appendix, Datasets S1 and S3) directed to 44 different membrane targets were
allowed to bind to LAX7D (blue) or LAX7R (red) cells. The average value from four replicates, with SD (gray bars), is shown. (C) Targets are shown that were
down- or up-regulated from LAX7D to LAX7R. (D) Experimental scheme for the P493-6 cell line in MycOFF and MycON conditions. Myc was repressed for
48 h with the addition of Tet (100 ng/mL, twice per day). The MycOFF state was harvested, Tet was washed out, and the cells recovered for 6 d before the
MycON condition was harvested. (E) The extended bar chart displays the results of the PhaNGS profiling for the MycOFF to MycON experiment (blue and
orange bars, respectively). The average value from four replicates, with SD (gray bars), is shown. (F) Targets are presented that were down- or up-regulated
when transitioning from MycOFF to MycON.
represents a major target of interest in ALL, chronic lymphocytic
leukemia (CLL), and other leukemias (18–20). Despite the vari-
ation in NGS signal between Fab-phage against the same target,
the ratio of the average fold-change between the LAX7D and
LAX7R states for a family of antibodies was consistent, provid-
ing additional confidence in the changes observed (SI Appendix,
Fig. S8A). The variation in relative NGS signal for antibodies to
the same targets is likely due to signal suppression for the weakly
bound antibodies, since signal-to-noise is less.
We also performed RNAseq on the LAX7D and LAX7R sam-
ples and identified 11 transcripts for which targets were also
present in the PhaNGS dataset (SI Appendix, Fig. S9). There was
a weak correlation in the fold-change for the common targets
(Pearson correlation coefficient, R = 0.17), possibly reflecting










differences in receptor translation, trafficking, and stability. Such
discrepancies between protein and RNA levels for mammalian
cytosolic proteins have been reported and highlight the need for
direct cell-surface protein quantitation (3).
PhaNGS Profiling of Myc-Induced Surface Proteomic Changes. Onco-
genes are known to induce significant changes in gene protein
expression. Myc shows especially strong perturbation in expres-
sion profiles (21). We wished to use PhaNGS to explore how
Myc expression alters the expression of surface targets in our
library. We used a model B cell line, P493-6, that has been used
to mimic Burkitt lymphoma (22). In these cells, Myc is expressed
at high levels but can be repressed by addition of Tet. We cul-
tured these cells, then repressed Myc expression by treating with
Tet for 2 d to generate the OFF state (Fig. 2D). The repression
of Myc stalled cell growth without inducing apoptosis and led
to subtle changes in morphology, as reported (23). Cells were
allowed to recover in the absence of Tet for 6 d to re-express
Myc, during which time cell growth and morphology returned to
that of the ON state. PhaNGS profiles were then generated for
cells from the OFF and ON states (Fig. 2E). The general pro-
file for the P493-6 B cells looks remarkably similar to that for
the patient-derived ALL cells (Fig. 2B). Myc re-expression lead
to down-regulation of NCR3LG1 (for most clones) and ROR1
and up-regulation of FLT3, PDGFRB, and PTK7 (Fig. 2F), the
same pattern of expression changes seen between the diagno-
sis and relapse ALL cells (Fig. 2C and SI Appendix, Fig. S10).
The fact that many of the same proteins exhibit similar changes
in both the LAX7 and P493-6 experiments suggests that among
these B cell subtypes, particular groups of receptors dominate
the response to these perturbations, as has been seen for EFG
stimulation in other cell types (24). It is noteworthy that the
PhaNGS profile for the HEK293T cells is considerably different
from the profile seen for the B cells, which suggests PhaNGS can
be used as a sensitive probe of cell type.
Comparison of the PhaNGS Method to Mass Spectrometry and Flow
Cytometry. We next compared fold-change values observed for
PhaNGS targets to those collected using more traditional pro-
tein detection methods. We used SILAC-based cell-surface cap-
ture (CSC) mass spectrometry to profile the fold-changes in cell-
surface proteins in P493-6 cells induced by Myc repression or in
MCF10A cells induced by KRASG12V and compared 12 common
targets to those observed in PhaNGS experiments on the same
cells (Fig. 3A). We found a good correlation (R = 0.66) despite
the sparse overlap from the small target set in the PhaNGS
pool and detection of mostly abundant glycoproteins in the CSC
experiments. We also expressed and purified two Fabs identified
from the PhaNGS experiments that were highly responsive in
the Myc-inducible experiment (NCR3LG1 and ROR1) and two
that were induced in the KRASG12V-transformed MCF10 cells
(ANPEP and CDCP1). All four targets showed the same direc-
tional change and roughly the same fold-change by flow cytome-
try and PhaNGS (Fig. 3B).
Single-Cell PhaNGS. The PhaNGS profiles to this point have been
on populations containing 1–10 × 106 cells. Bulk measurements
of cancer cell populations can neglect to identify important
nuances in cellular heterogeneity revealed by single-cell analysis
(25). To extend the reach of the method, we sought to develop
single-cell PhaNGS (SI Appendix, Fig. S11A). Here, Fab-phages
were added to a population of cells, and then individual cells
were flow-sorted into wells and each was profiled by NGS. We
tested the single-cell method on HEK293T cells overexpressing
cell surface-anchored GFP cells using GFP, CD55, CDCP1, and
GHR-Fab phage (SI Appendix, Fig. S10B). For each of the 62
cells tested, we only observed a signal for the GFP-Fab-phage,
as expected. We then tested single-cell PhaNGS on P493-6 cells
against three targets we found via flow cytometry to exhibit dis-
similar distributions of protein abundance (Fig. 4A). Our single-
cell PhaNGS experiment found that for 84 single cells, the distri-
butions observed by flow were closely recapitulated by PhaNGS
(Fig. 4B).
Discussion
We believe that PhaNGS represents an important advance in
barcoded antibody technology. This initial PhaNGS demonstra-
tion using ∼150 antibodies is to our knowledge the largest
simultaneous use of defined antibodies yet published, surpass-
ing the theoretical limit for fluorophores using immunofluores-
cence (26), mass tags using CyTOF (27–30), or what has thus
far been achieved using oligonucleotide-based barcodes (31).
Moreover, we estimate a fixed cost of about $2 per replicate
for each PhaNGS profile because the Fab-phages are genetically
A B
Fig. 3. Comparison of PhaNGS to established proteomic methods. (A) Comparison of fold-changes in surface expression of indicated surface proteins pre–
and post–2-d suppression of Myc in P493-6 B cells or for empty vector to KRASG12V transformation of MCF10A cells as assessed by PhaNGS and Stable
Isotope Labeling by Amino Acids in Cell Culture (SILAC) mass spectrometry. Dot size indicates spectral counts for mass spectrometry experiments to imply the
abundance of each protein. Identity (y = x, gray dashed line) is shown as a benchmark for perfect agreement between MS and PhaNGS. R = 0.66 (regression
line not pictured, y = 0.98x0.62). Where applicable, error bars for PhaNGS fold-change represent SD derived from unique Fab-phages against the same target.
(B) Flow data corresponding to mass spectrometry vs. PhaNGS data for ANPEP, CDCP1, NCR3LG1, and ROR1. The fold-change values observed in the flow
cytometry experiments closely match those observed for PhaNGS.
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Fig. 4. Single-cell PhaNGS on P493-6 cells. (A) Flow cytometry histograms on a population of P493-6 MycON cells (n = 12,000), using purified Fabs for ROR1
(clone ROR1.02, Left), insulin receptor (clone INSR.01, Middle), and NCR3LG1 (clone NCR3LG1.06, Right). Log fluorescence values are indicated on the x axis
(anti–FLAG-APC). ROR1 shows bimodal expression with a small low-signal peak and large high-signal peak, INSR shows unimodal expression, and NCR3LG1
shows bimodal expression with a large low-signal peak and small high-signal peak. (B) Results from single-cell PhaNGS using the corresponding ROR1, INSR,
and NCR3LG1 Fab-phage antibodies on 84 individual P493-6 cells match observations from flow cytometry.
encoded and renewable (SI Appendix, Table S1). This com-
pares with expensive and perishable antibody reagents needed
for probe conjugation using other technologies. Although the
PhaNGS experiments presented here were conducted with fewer
than 200 unique Fab-phages, we estimate that PhaNGS could
profile a target multiplicity of tens of thousands based on exper-
iments using dilute input libraries.
Given the growing interest in the development of renewable
antibodies (32) and the ability to industrialize their selection
(5), we believe the PhaNGS technology will undergo tremen-
dous growth in the size of the probe library in the next few
years. Moreover, the application of microfluidic technology to
the method will increase its use for single-cell analysis and
could allow for simultaneous RNAseq-PhaNGS experiments.
The method may also be amenable to alternative display sys-
tems such as ribosome display (33). Having identified Fab-
phage hits, one can easily transition the recombinant antibody
into a multitude of detection or bioengineered formats such
as antibody–drug conjugates (ADCs), bispecific T-cell engagers
(BiTEs), or chimeric antigen receptor (CAR) T cells. We believe
the PhaNGS method will have general utility to profile how
cell-surface proteins change in health and disease. Such data
will be useful for identifying new combinatorial biomarkers and
drug targets.
Materials and Methods
Patient Samples. Patient-derived leukemia samples were collected with
informed consent from all participants according to NCI/Cancer Therapy
Evaluation Program-approved protocol ECOG E2993T5 and studied with
approval of the Institutional Review Boards of the University of California
San Francisco (UCSF). The samples were taken as bone marrow biopsies, blast
content >80%.
Preparing Phage Input Libraries. The PhaNGS input pool was constructed as
follows: 5 µL of each clone was transferred to respective wells of a 96-well
round-bottom plate (Corning). Then, 100 µL log phase XL-1 blue cells (Agi-
lent, OD600 = 0.6–0.7) were added to each well before the plate was covered
in a gas-permeable film (Diversified Biotech) and placed at 37 ◦C for 20 min.
We then transferred 100 µL of infected cells to respective wells of a 96-well
deep-well plate (Corning Axygen) containing 400 µL per well 2xYT broth
with 100 µg/mL carbenicillin and 1010 cfu/mL KO7 helper phage (NEB).
The deep-well plate was covered in a gas-permeable film and shaken at
1000 rpm and 37 ◦C for 18–24 h in an Infors HT shaker. Plates were spun
down at 4,000 g for 15 min at room temperature, and the supernatant was
consolidated into 50 mL tubes before adding 0.02% sodium azide and stor-
ing at 4 ◦C. This method leads to approximately equal quantities of each
clone from a propagated supernatant (roughly 1011 cfu/mL total).
Panning Phage on Cells. Cells were washed once (to remove media, DMSO)
by spinning the cells down at 300 g for 5 min at 4 ◦C, pouring off the super-
natant into liquid waste, resuspending in 1 mL cold PBS, spinning down,
and decanting again. The final drops during decanting were removed by
inverting and dabbing the tube on a paper towel. The washed cell pellet
was then resuspended in 1 mL of the input phage mixture prepared above.
The tube was end-over-end rotated for 20 min at 4 ◦C before spinning down
and decanting as above. Cells were then washed four times with PBS, trans-
ferring to fresh 2 mL Eppendorf tubes, and inverting to coat the walls each
time. To elute cell-bound phage, the pellet was resuspended in 900 µL of 0.1
M acetic acid, pH 2–3, allowed to sit for 5 min, spun down, and 800 µL of
the acid eluent was transferred to a 1.5 mL Eppendorf tube containing 100
µL 1 M Tris, pH 7.5, to neutralize. The neutralized solution was propagated
as described above for the input pool or by flask (see SI Appendix). After
propagation for 16 to 18 h, 50 µL of propagated phage were transferred to
a 96-well PCR plate and boiled.
For single-cell experiments, instead of elution, single cells were sorted by
forward and side scatter (or fluorescence) into each well of a 96-well plate
containing 50 µL of 2xYT broth, then propagated via addition of 100 µL log
phase XL-1 culture.
Amplification and Purification. The H3 “barcode” of each phagemid was
amplified using boiled propagate template and flanking primers using Phu-
sion polymerase (NEB). See Dataset S4 for primer design. The complete
mix was then thermocycled for 12 cycles. Those samples showing bands
by agarose gel were combined, gel purified, and submitted to a sequenc-
ing facility for analysis on a HiSeq4000 (Illumina) with a custom sequencing
primer (order as shown): TGAGGACACTGCCGTCTATTATTGTGCTCGC (Tm =
67 ◦C, GC% = 52).
Mass Spectrometry. Cell samples were generated by SILAC as described
previously (34). Mass spectrometry work-up was performed as described
previously (35). Samples were run on a Q-Exactive Mass Spectrometer
(ThermoScientific Inc.). Data were analyzed using MaxQuant (36). Median
SILAC ratio values were used to determine fold-change values between
conditions.
Code Availability. See https://github.com/sbpollock/PhaNGS-counting for
scripts and details on how to convert “.fastq.gz” sequencing files into counts.
See Dataset S3 for details on how these counts are interpreted.
Statistics. Error bars represent SD, which was calculated using Excel’s
STDEV.P function (see Dataset S3). Student’s t test was performed using
Excel’s T.TEST function (two-tailed, homoscedastic).
Data Archival. The sequencing data that support the findings of this study
are available in the Gene Expression Omnibus (GEO) with the identifier
GSE102712 for PhaNGS data and GSE102301 for RNAseq data. All other data
supporting the findings of this study are available within the SI Appendix,
Dataset S3.
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